MDxHealth expects to be key Dutch provider of urine-based prostate cancer testing
This article was originally published in Clinica
MDxHealth has launched a new liquid biopsy prostate cancer test, SelectMDx, in Europe, a month after gaining the technology through the acquisition of its developer NovioGendix. The test will be offered through NovioGendix’s lab facilities in Nijmegen, the Netherlands, which MDxHealth also acquired.
Register for our free email digests: